Board of Directors
News & Events
Investors & Partnering
Why invest in SolAeroMed
Recruiting CF Patients
Now Recruiting CF Patients
SolAeroMed S-1226 COVID-19 Media Room
<a href="https://www.solaeromed.com/logo-image/">Logo Image</a>
$1.5 million investment round announced to progress COVID -19 clinical trial
We have constructed a term sheet to raise $1.5 million to support a Phase II clinical trial in COVID patients in local Alberta hospitals. We maintain the current $7.50...
Health Canada signs regulatory approval for S-1226 COVID Phase II clinical trial
On the eve of 2021 SolAeroMed received regulatory notification from Health Canada that our proposed clinical trial of S-1226 in COVID patients received official approval. This is approval was...
SolAeroMed advances discussion with European partners on development of S-1229 as platform drug technology based on granting of European cyclodextrin patent.
While most of SolAeroMed efforts are focused on advancing clinical trial development of our lead CO2/perflubron S-1226 drug, we have also made recent progress in our S-1229 Cyclodextrin drug...